Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease
Identifieur interne : 001D72 ( Main/Exploration ); précédent : 001D71; suivant : 001D73Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease
Auteurs : Taylor [Royaume-Uni] ; Beerahee [Royaume-Uni] ; Citerone [États-Unis] ; Cyronak [États-Unis] ; Leigh [Royaume-Uni] ; Fitzpatrick [Royaume-Uni] ; Lopez‐Gil [Royaume-Uni] ; Vakil [Royaume-Uni] ; Burns [Royaume-Uni] ; Lennox [Royaume-Uni]Source :
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [ 0277-0008 ] ; 1999-02.
Abstract
Study Objective. To assess the interaction between therapeutic dosages of ropinirole and l‐dopa plus a decarboxylase inhibitor administered at steady state in patients with Parkinson's disease. Design. Open, 6‐week, overlap trial with random allocation. Patients. Thirty patients with Parkinson's disease not previously treated with dopamine agonists, of whom 28 produced evaluable pharmacokinetic data for ropinirole and 23 for l‐dopa. Intervention. Group A (14 patients) received l‐dopa for weeks 1–5 and ropinirole in increasing increments for weeks 2–6; group B (16) received ropinirole for weeks 1–5 and l‐dopa for weeks 5 and 6. Measurements and Main Results. Primary end points were AUC0–8 and Cmax for ropinirole, and AUC0–8, AUC0–∞, and Cmax for l‐dopa. Secondary end points were Tmax for ropinirole, and Tmax and half‐life for l‐dopa. Coadministration with l‐dopa at steady state did not affect rate or extent of availability of ropinirole: point estimates of the geometric mean ratio for ropinirole plusl‐dopa compared with ropinirole alone for both Cmax and AUC0–8 approximated to unity. The small (16%) increase in peak concentrations of l‐dopa on administration with ropinirole is unlikely to be of clinical consequence, as peak concentrations of l‐dopa are typically highly variable. Conclusion. There are no pharmacokinetic grounds for adjusting dosages of either ropinirole or l‐dopa when given in combination.
Url:
DOI: 10.1592/phco.19.3.150.30927
Affiliations:
- Royaume-Uni, États-Unis
- Angleterre, Nottinghamshire, Pennsylvanie
- Nottingham
- Université de Nottingham
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease</title><author><name sortKey="Taylor" sort="Taylor" uniqKey="Taylor" last="Taylor">Taylor</name></author><author><name sortKey="Beerahee" sort="Beerahee" uniqKey="Beerahee" last="Beerahee">Beerahee</name></author><author><name sortKey="Citerone" sort="Citerone" uniqKey="Citerone" last="Citerone">Citerone</name></author><author><name sortKey="Cyronak" sort="Cyronak" uniqKey="Cyronak" last="Cyronak">Cyronak</name></author><author><name sortKey="Leigh" sort="Leigh" uniqKey="Leigh" last="Leigh">Leigh</name></author><author><name sortKey="Fitzpatrick" sort="Fitzpatrick" uniqKey="Fitzpatrick" last="Fitzpatrick">Fitzpatrick</name></author><author><name sortKey="Lopez Il" sort="Lopez Il" uniqKey="Lopez Il" last="Lopez-Gil">Lopez‐Gil</name></author><author><name sortKey="Vakil" sort="Vakil" uniqKey="Vakil" last="Vakil">Vakil</name></author><author><name sortKey="Burns" sort="Burns" uniqKey="Burns" last="Burns">Burns</name></author><author><name sortKey="Lennox" sort="Lennox" uniqKey="Lennox" last="Lennox">Lennox</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6B28CFE35845D2F5E32F106220EB410AC14DA734</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1592/phco.19.3.150.30927</idno><idno type="url">https://api.istex.fr/document/6B28CFE35845D2F5E32F106220EB410AC14DA734/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002202</idno><idno type="wicri:Area/Main/Curation">001E92</idno><idno type="wicri:Area/Main/Exploration">001D72</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease</title><author><name sortKey="Taylor" sort="Taylor" uniqKey="Taylor" last="Taylor">Taylor</name><affiliation wicri:level="1"><country>Royaume-Uni</country><wicri:regionArea>Division of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts</wicri:regionArea><wicri:noRegion>Herts</wicri:noRegion></affiliation></author><author><name sortKey="Beerahee" sort="Beerahee" uniqKey="Beerahee" last="Beerahee">Beerahee</name><affiliation wicri:level="1"><country>Royaume-Uni</country><wicri:regionArea>Division of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts</wicri:regionArea><wicri:noRegion>Herts</wicri:noRegion></affiliation></author><author><name sortKey="Citerone" sort="Citerone" uniqKey="Citerone" last="Citerone">Citerone</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia</wicri:cityArea></affiliation></author><author><name sortKey="Cyronak" sort="Cyronak" uniqKey="Cyronak" last="Cyronak">Cyronak</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia</wicri:cityArea></affiliation></author><author><name sortKey="Leigh" sort="Leigh" uniqKey="Leigh" last="Leigh">Leigh</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Divisions of Clinical Pharmacology SmithKline Beecham Pharmaceuticals, Harlow, Essex</wicri:regionArea><wicri:noRegion>Essex</wicri:noRegion></affiliation></author><author><name sortKey="Fitzpatrick" sort="Fitzpatrick" uniqKey="Fitzpatrick" last="Fitzpatrick">Fitzpatrick</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Clinical Pharmacology Statistics (Ms. Fitzpatrick), SmithKline Beecham Pharmaceuticals, Harlow, Essex</wicri:regionArea><wicri:noRegion>Essex</wicri:noRegion></affiliation></author><author><name sortKey="Lopez Il" sort="Lopez Il" uniqKey="Lopez Il" last="Lopez-Gil">Lopez‐Gil</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Divisions of Clinical Pharmacology SmithKline Beecham Pharmaceuticals, Harlow, Essex</wicri:regionArea><wicri:noRegion>Essex</wicri:noRegion></affiliation></author><author><name sortKey="Vakil" sort="Vakil" uniqKey="Vakil" last="Vakil">Vakil</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Preston Hospital, Fulwood, Preston, Lancashire</wicri:regionArea><wicri:noRegion>Lancashire</wicri:noRegion></affiliation></author><author><name sortKey="Burns" sort="Burns" uniqKey="Burns" last="Burns">Burns</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Leeds General Infirmary, Leeds, West Yorkshire</wicri:regionArea><wicri:noRegion>West Yorkshire</wicri:noRegion></affiliation></author><author><name sortKey="Lennox" sort="Lennox" uniqKey="Lennox" last="Lennox">Lennox</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Queens Medical Centre, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</title><idno type="ISSN">0277-0008</idno><idno type="eISSN">1875-9114</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1999-02">1999-02</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="150">150</biblScope><biblScope unit="page" to="156">156</biblScope></imprint><idno type="ISSN">0277-0008</idno></series><idno type="istex">6B28CFE35845D2F5E32F106220EB410AC14DA734</idno><idno type="DOI">10.1592/phco.19.3.150.30927</idno><idno type="ArticleID">PHAR741</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Study Objective. To assess the interaction between therapeutic dosages of ropinirole and l‐dopa plus a decarboxylase inhibitor administered at steady state in patients with Parkinson's disease. Design. Open, 6‐week, overlap trial with random allocation. Patients. Thirty patients with Parkinson's disease not previously treated with dopamine agonists, of whom 28 produced evaluable pharmacokinetic data for ropinirole and 23 for l‐dopa. Intervention. Group A (14 patients) received l‐dopa for weeks 1–5 and ropinirole in increasing increments for weeks 2–6; group B (16) received ropinirole for weeks 1–5 and l‐dopa for weeks 5 and 6. Measurements and Main Results. Primary end points were AUC0–8 and Cmax for ropinirole, and AUC0–8, AUC0–∞, and Cmax for l‐dopa. Secondary end points were Tmax for ropinirole, and Tmax and half‐life for l‐dopa. Coadministration with l‐dopa at steady state did not affect rate or extent of availability of ropinirole: point estimates of the geometric mean ratio for ropinirole plusl‐dopa compared with ropinirole alone for both Cmax and AUC0–8 approximated to unity. The small (16%) increase in peak concentrations of l‐dopa on administration with ropinirole is unlikely to be of clinical consequence, as peak concentrations of l‐dopa are typically highly variable. Conclusion. There are no pharmacokinetic grounds for adjusting dosages of either ropinirole or l‐dopa when given in combination.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Nottinghamshire</li><li>Pennsylvanie</li></region><settlement><li>Nottingham</li></settlement><orgName><li>Université de Nottingham</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Taylor" sort="Taylor" uniqKey="Taylor" last="Taylor">Taylor</name></noRegion><name sortKey="Beerahee" sort="Beerahee" uniqKey="Beerahee" last="Beerahee">Beerahee</name><name sortKey="Burns" sort="Burns" uniqKey="Burns" last="Burns">Burns</name><name sortKey="Fitzpatrick" sort="Fitzpatrick" uniqKey="Fitzpatrick" last="Fitzpatrick">Fitzpatrick</name><name sortKey="Leigh" sort="Leigh" uniqKey="Leigh" last="Leigh">Leigh</name><name sortKey="Lennox" sort="Lennox" uniqKey="Lennox" last="Lennox">Lennox</name><name sortKey="Lopez Il" sort="Lopez Il" uniqKey="Lopez Il" last="Lopez-Gil">Lopez‐Gil</name><name sortKey="Vakil" sort="Vakil" uniqKey="Vakil" last="Vakil">Vakil</name></country><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Citerone" sort="Citerone" uniqKey="Citerone" last="Citerone">Citerone</name></region><name sortKey="Cyronak" sort="Cyronak" uniqKey="Cyronak" last="Cyronak">Cyronak</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6B28CFE35845D2F5E32F106220EB410AC14DA734
|texte= Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |